A significant proportion of endogenously processed CD8+ T cell epitopes are derived from newly synthesized proteins and rapidly degrading polypeptides (RDPs). It has been hypothesized that the generation of rapidly degrading polypeptides and CD8+ T cell epitopes from these RDP precursors may be influenced by the efficiency of protein translation. Here we address this hypothesis by using the Epstein-Barr virus–encoded nuclear antigen 1 protein (EBNA1), with or without its internal glycine-alanine repeat sequence (EBNA1 and EBNA1ΔGA, respectively), which display distinct differences in translation efficiency. We demonstrate that RDPs constitute a significant proportion of newly synthesized EBNA1 and EBNA1ΔGA and that the levels of RDPs produced by each of these proteins directly correlate with the translation efficiency of either EBNA1 or EBNA1ΔGA. As a consequence, a higher number of major histocompatibility complex–peptide complexes can be detected on the surface of cells expressing EBNA1ΔGA, and these cells are more efficiently recognized by virus-specific cytotoxic T lymphocytes compared to the full-length EBNA1. More importantly, we also demonstrate that the endogenous processing of these CD8+ T cell epitopes is predominantly determined by the rate at which the RDPs are generated rather than the intracellular turnover of these proteins.
Skip Nav Destination
Article navigation
19 March 2007
Article|
February 20 2007
Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes
Judy Tellam,
Judy Tellam
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Search for other works by this author on:
Mark H. Fogg,
Mark H. Fogg
2Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Michael Rist,
Michael Rist
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Search for other works by this author on:
Geoff Connolly,
Geoff Connolly
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Search for other works by this author on:
David Tscharke,
David Tscharke
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Search for other works by this author on:
Natasha Webb,
Natasha Webb
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Search for other works by this author on:
Lea Heslop,
Lea Heslop
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Search for other works by this author on:
Fred Wang,
Fred Wang
2Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115
Search for other works by this author on:
Rajiv Khanna
Rajiv Khanna
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Search for other works by this author on:
Judy Tellam
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Mark H. Fogg
2Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115
Michael Rist
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Geoff Connolly
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
David Tscharke
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Natasha Webb
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Lea Heslop
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
Fred Wang
2Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115
Rajiv Khanna
1Australian Centre for Vaccine Development and Tumour Immunology Laboratory, Division of Infectious Diseases and Immunology, Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Brisbane (Qld) 4006, Australia
CORRESPONDENCE Rajiv Khanna: [email protected] OR Judy Tellam: [email protected]
Abbreviations used: DRiP, defective ribosomal product; EBNA1, EBV-encoded nuclear antigen 1 protein; LCL, lymphoblastoid cell line; RDP, rapidly degrading polypeptide.
J. Tellam and M.H. Fogg contributed equally to this work.
Received:
November 29 2006
Accepted:
January 18 2007
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2007
J Exp Med (2007) 204 (3): 525–532.
Article history
Received:
November 29 2006
Accepted:
January 18 2007
Connected Content
Related
Translated to death
Citation
Judy Tellam, Mark H. Fogg, Michael Rist, Geoff Connolly, David Tscharke, Natasha Webb, Lea Heslop, Fred Wang, Rajiv Khanna; Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes . J Exp Med 19 March 2007; 204 (3): 525–532. doi: https://doi.org/10.1084/jem.20062508
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
See also
Email alerts
Advertisement